Logo Logo
Hilfe
Hilfe
Switch Language to English

Karschnia, Philipp; Teske, Nico; Dorostkar, Mario M.; Siller, Sebastian; Weller, Jonathan; Baehring, Joachim M.; Dietrich, Jörg; Baumgarten, Louisa von; Herms, Jochen; Tonn, Jörg-Christian und Thon, Niklas (2020): Extent and prognostic value of MGMT promotor methylation in glioma WHO grade II. In: Scientific Reports, Bd. 10, Nr. 1, 19758 [PDF, 2MB]

Abstract

MGMT promotor methylation is associated with favourable outcome in high-grade glioma. In glioma WHO grade II, it is unclear whether the extent of MGMT promotor methylation and its prognostic role is independent from other molecular markers. We performed a retrospective analysis of 155 patients with glioma WHO grade II. First, all 155 patients were assigned to three molecular groups according to the 2016 WHO classification system: (1) oligodendroglioma, IDH-mutant and 1p19q co-deleted (n=81);(2) astrocytoma, IDH-mutant and 1p19q non-codeleted (n=54);(3) astrocytoma, IDH-wildtype (n=20). MGMT promotor methylation was quantified using Sanger sequencing of the CpG sites 74-98 within the MGMT promotor region. Highest numbers of methylated CpG sites were found for oligodendroglioma, IDH-mutant and 1p19q co-deleted. When 1p19q co-deletion was absent, numbers of methylated CpG sites were higher in the presence of IDH-mutation. Accordingly, lowest numbers were seen in the IDH-wildtype subpopulation. In the entire cohort, larger numbers of methylated CpG sites were associated with favourable outcome. When analysed separately for the three WHO subgroups, a similar association was only retained in astrocytoma, IDH-wildtype. Collectively, extent of MGMT promotor methylation was strongly associated with other molecular markers and added prognostic information in astrocytoma, IDH-wildtype. Evaluation in prospective cohorts is warranted.

Dokument bearbeiten Dokument bearbeiten